Back to search results

MEDI5752 for Unresectable Pleural Mesothelioma

This study is testing a new combination of medicines for people with unresectable pleural mesothelioma, a type of cancer that cannot be removed by surgery. It compares a new drug called Volrustomig (MEDI5752) given with Carboplatin and Pemetrexed, against standard treatments like platinum-based chemotherapy with Pemetrexed, or Nivolumab with Ipilimumab. The main goal is to see if the new combination helps people live longer. You might be able to join if you are 18 or older, have a confirmed diagnosis of unresectable pleural mesothelioma, and meet certain health criteria. The study plans to enroll 863 participants, but its current recruitment status is unclear.

Study design
This is a Phase 3, randomized, open-label study involving 863 participants. You would be randomly assigned to receive either the new drug combination or a standard treatment.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for overall survival for up to approximately 61 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06097728

MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

Active, Not Recruiting
PHASE3Ages 18+InterventionalTreatment
AstraZeneca
~863 participants
Updated 2026-07-28 on ClinicalTrials.gov
What's tested:VolrustomigPemetrexedCarboplatinCisplatinNivolumabIpilimumab

At a glance

Recruiting sites
0 of 151 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Overall Survival (OS) in experimental arm relative to comparator arm
Measured over up to approximately 61 months

Conditions

Unresectable Pleural Mesothelioma

Explore related trials

Pleural Malignant Mesothelioma

Where it's being run

151 sites across 35 states
China22
Germany13
France12
Japan12
Italy10
United Kingdom10
South Africa7
Brazil6

Study leadership

  • Marjorie G Zauderer, MD · PRINCIPAL_INVESTIGATOR · Memorial Slone Kettering (MSK) Cancer Centre
  • Arnaud Scherpereel, MD · PRINCIPAL_INVESTIGATOR · Lille University

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participant must be ≥ 18 years at the time of screening
Histologically proven diagnosis of pleural mesothelioma with known histology (epithelioid vs. non-epithelioid)
Advanced unresectable disease that cannot be treated with curative surgery (with or without chemotherapy)
WHO/ECOG performance status of 0 or 1 with no deterioration (that is, ECOG PS\>1) over the previous 2 weeks prior to day of first dosing
Has measurable disease per modified RECIST1.1
Has adequate bone marrow reserve and organ function at baseline

Exclusion

As judged by the investigator, any condition that would interfere with evaluation of the investigational product or interpretation of participant safety or study results.
Active or prior documented autoimmune or inflammatory disorders
History of another primary malignancy with exceptions.
Uncontrolled intercurrent illness
Tuberculosis, hepatitis B (HBV) or hepatitis C (HCV), human immunodeficiency virus (HIV) infection that is not well controlled
Any concurrent chemotherapy, radiotherapy, investigational, biologic, or hormonal therapy for cancer treatment
Untreated or progressive CNS metastatic disease

What this trial measures

  • Overall Survival (OS) in experimental arm relative to comparator armup to approximately 61 months

    OS is defined as the time from randomization until the date of death due to any cause.